Health Library & Tools

News

New radiation treatment option available at Aspirus

Mar 28, 2014

WAUSAU, Wis. – Doctors at Aspirus Regional Cancer Center recently began treating patients with a new radiation technology called HDR (High Dose Rate) Brachytherapy.

HDR Brachytherapy is a very precise and highly effective form of radiation therapy, in which the radiation source that delivers the required dose of radiation is placed in or close to the tumor itself. The precision of HDR Brachytherapy allows physicians to concentrate a high dose of radiation in a small volume, minimizing damage to nearby, healthy body tissue and organs.

HDR Brachytherapy offers short treatment times that are typically just a few minutes over a few days to a few weeks, along with short recovery periods. This method of treatment offers patient benefits such as:

  • Shorter treatment time.
  • Shorter recovery times.
  • Less frequent visits to the hospital.
  • Minimal side effects.
  • Greater comfort for patient during treatment.

“HDR Brachytherapy is a great advancement in the way radiation therapy can be delivered and we are excited to be able to offer it as a treatment option for our patients,” said Darryl Barton, M.D., radiation oncologist at Aspirus Regional Cancer Center. 

HDR Brachytherapy is the latest radiation therapy technology available at Aspirus, which also utilizes Tomotherapy, Intensity Modulated Radiotherapy Treatment (IMRT), LDR Brachytherapy and 3-D radiation therapy to treat patients. HDR Brachytherapy can be used in conjunction with these other treatments or as an alternative stand-alone option for the treatment of numerous types of cancers, including breast, gynecologic, skin, prostate, lung, esophageal and rectal cancers.  

“Each patient is different, so it’s important to have multiple treatment options available because a technology or method of treatment that is effective for one patient may not be appropriate for others,” Dr. Barton said. “The addition of HDR Brachytherapy allows us to consider even more options when determining the technology or combination of treatments that will best serve each patient.”